866774-35-8Relevant articles and documents
Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes
Bebernitz, Gregory R.,Beaulieu, Valerie,Dale, Bethany A.,Deacon, Richard,Duttaroy, Alokesh,Gao, Jiaping,Grondine, Melissa S.,Gupta, Ramesh C.,Kakmak, Mesut,Kavana, Michael,Kirman, Louise C.,Liang, Jinsheng,Maniara, Wieslawa M.,Munshi, Siralee,Nadkarni, Sunil S.,Schuster, Herbert F.,Stams, Travis,St. Denny, Irene,Taslimi, Paul M.,Vash, Brian,Caplan, Shari L.
experimental part, p. 6142 - 6152 (2010/02/28)
Type 2 diabetes is a polygenic disease which afflicts nearly 200 million people worldwide and is expected to increase to near epidemic levels over the next 10-15 years. Glucokinase (GK) activators are currently under investigation by a number of pharmaceu
SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL THE TREATMENT OF TYPE 2 DIABETES
-
Page/Page column 46, (2010/02/14)
The present invention provides compounds of the formula (I), which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, Type 2 diabetes and obesity.
